Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females
Effect of Steady State Meloxicam 15 mg/Day on Low Dose Aspirin (100 mg/Day) Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females. An Open, Randomised, Two-way Crossover Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female subjects as determined by results of screening
- Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- Age >=18 and <= 60 years
- The Body Mass Index (BMI) ≥ 18.5 kg/m2 (square meters) and ≤ 29.9 kg/m2.
- Laboratory values within a clinical normal range
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastro-intestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- Use of any drugs, which might influence the results of the trial, in particular aspirin containing drugs(< 14 days prior to administration or during the trial)
- Participation in another trial with an investigational drug (< 1 months prior to administration (at least 10 times the relevant elimination half-life) or during trial)
- Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life)
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (> 60 grams (g)/day)
- Drug abuse
- Blood donation or loss > 400 mL (< 1 month prior to administration or during the trial)
- Excessive physical activities (< 5 days prior to administration or during the trial)
- Any ECG value outside of the reference range of clinical relevance including, but not limited to QTcB > 480 ms or QRS interval > 110 ms
- History of any familial bleeding disorder
- History of haemorrhagic diatheses
- History of gastrointestinal ulcer, perforation or bleeding
- History of bronchial asthma
- Inability to comply with dietary regimen of study centre
- Inability to comply with investigator's instructions
For female subjects:
- Pregnancy
- Positive pregnancy test
- No adequate contraception (e.g. sterilisation, intrauterine device (IUP), oral contraceptives)
- Inability to maintain this adequate contraception during the whole study period
- Lactation period
Ovarian hormone substitution and oral contraception have to be continued during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Meloxicam/Aspirin
Meloxicam days 1-10 / Aspirin days 5-10
|
|
|
Active Comparator: Aspirin
Aspirin 2 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Arachidonic acid induced platelet aggregation
Time Frame: up to day 11 (treatment 1), up to day 3 (treatment 2)
|
up to day 11 (treatment 1), up to day 3 (treatment 2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with adverse events
Time Frame: up to 6 weeks
|
up to 6 weeks
|
|
Collagen-induced Platelet Aggregation
Time Frame: up to day 11 (treatment 1), up to day 3 (treatment 2)
|
up to day 11 (treatment 1), up to day 3 (treatment 2)
|
|
Adenosine diphosphate (ADP) Induced Platelet Aggregation
Time Frame: up to day 11 (treatment 1), up to day 3 (treatment 2)
|
up to day 11 (treatment 1), up to day 3 (treatment 2)
|
|
Serum Thromboxane B2 production
Time Frame: up to day 11 (treatment 1), up to day 3 (treatment 2)
|
up to day 11 (treatment 1), up to day 3 (treatment 2)
|
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: up to day 11 (treatment 1), up to day 3 (treatment 2)
|
up to day 11 (treatment 1), up to day 3 (treatment 2)
|
|
Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)
Time Frame: Screening, 24 hours after the last Aspirin intake
|
Screening, 24 hours after the last Aspirin intake
|
|
Number of patients with clinically significant changes in vital signs
Time Frame: Screening, 24 hours after the last Aspirin intake
|
Screening, 24 hours after the last Aspirin intake
|
|
Assessment of tolerability on a 4-point scale
Time Frame: 24 hours after the last Aspirin intake
|
24 hours after the last Aspirin intake
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Cyclooxygenase 2 Inhibitors
- Aspirin
- Meloxicam
Other Study ID Numbers
Other Study ID Numbers
- 107.255
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.